Acasti Pharma Total Long-Term Assets 2014-2024 | GRCE
Acasti Pharma total long-term assets from 2014 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
Acasti Pharma Annual Total Long-Term Assets (Millions of US $) |
2024 |
$49 |
2023 |
$50 |
2022 |
$83 |
2021 |
$0 |
2020 |
$4 |
2019 |
$9 |
2018 |
$11 |
2017 |
$12 |
2016 |
$13 |
2015 |
$16 |
2015 |
$ |
2014 |
$19 |
2014 |
$ |
2013 |
$6 |
2013 |
$ |
Acasti Pharma Quarterly Total Long-Term Assets (Millions of US $) |
2024-06-30 |
$49 |
2024-03-31 |
$49 |
2023-12-31 |
$49 |
2023-09-30 |
$49 |
2023-06-30 |
$49 |
2023-03-31 |
$50 |
2022-12-31 |
$83 |
2022-09-30 |
$83 |
2022-06-30 |
$84 |
2022-03-31 |
$83 |
2021-12-31 |
$65 |
2021-09-30 |
$65 |
2021-06-30 |
$0 |
2021-03-31 |
$0 |
2020-12-31 |
$0 |
2020-09-30 |
$0 |
2020-06-30 |
$6 |
2020-03-31 |
$4 |
2019-12-31 |
$7 |
2019-09-30 |
$8 |
2019-06-30 |
$8 |
2019-03-31 |
$9 |
2018-12-31 |
$9 |
2018-09-30 |
$10 |
2018-06-30 |
$10 |
2018-03-31 |
$11 |
2017-12-31 |
$11 |
2017-09-30 |
$11 |
2017-06-30 |
$11 |
2017-02-28 |
$12 |
2016-11-30 |
$12 |
2016-08-31 |
$12 |
2016-05-31 |
$13 |
2016-03-31 |
$13 |
2016-02-29 |
|
2015-12-31 |
$12 |
2015-09-30 |
$13 |
2015-06-30 |
$14 |
2015-03-31 |
$16 |
2014-12-31 |
$16 |
2014-09-30 |
$17 |
2014-06-30 |
$17 |
2014-03-31 |
$19 |
2014-02-28 |
|
2013-12-31 |
$19 |
2013-09-30 |
$20 |
2013-06-30 |
$6 |
2013-03-31 |
$6 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|